You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 開拓藥業-B(9939.HK)漲超5% 新藥研究申請獲國家藥監局CDE批准
格隆匯 04-16 10:25
格隆匯4月16日丨開拓藥業-B(9939.HK)現報37.45港元,漲5.05%,暫成交3822萬港元,最新總市值138億港元。開拓藥業昨日晚間公佈,於4月14日,GT20029用於雄激素性脱髮及痤瘡適應症的新藥研究("IND")申請("臨牀試驗")已獲中國國家藥品監督管理局藥品審評中心("CDE")批准。臨牀試驗為隨機、雙盲、安慰劑對照的I期研究,旨在評估GT20029酊凝膠在健康受試者中單、多次給藥的安全性及藥代動力學特性。集團正準備臨牀試驗,並預期將於2021年第三季開始招募受試者。據董事所知,GT20029是全球首個進入臨牀階段的外用PROTAC化合物。集團亦正在準備GT20029於美國的IND申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account